These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 26308222

  • 1. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V, Patel H, Kurlander JL, Essoi B, Yang J, Mahableshwarkar AR, Samp JC, Akhras KS.
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [Abstract] [Full Text] [Related]

  • 2. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK, Kruzikas DT, McLaughlin TP.
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [Abstract] [Full Text] [Related]

  • 3. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J, Joish V.
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [Abstract] [Full Text] [Related]

  • 4. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW.
    J Manag Care Pharm; 2006 Dec; 12(1):43-54. PubMed ID: 16420107
    [Abstract] [Full Text] [Related]

  • 5. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A, Devine ST, Eichholz J, Kautzner A.
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [Abstract] [Full Text] [Related]

  • 6. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G, Zhang L, DiBernardo A, Wang G, Sheehan JJ, Lee K, Reutfors J, Zhang Q.
    PLoS One; 2020 Mar; 15(9):e0238843. PubMed ID: 32915863
    [Abstract] [Full Text] [Related]

  • 7. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [Abstract] [Full Text] [Related]

  • 8. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
    Zhu L, Ferries E, Suthoff E, Namjoshi M, Bera R.
    J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M, Teeple A, Pilon D, Shah A, Caron-Lapointe G, Joshi K.
    J Med Econ; 2023 Nov; 26(1):691-700. PubMed ID: 37130075
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV, Singer ME, Jhaveri M, Chung H, Miller A.
    J Manag Care Pharm; 2010 Nov; 16(9):703-12. PubMed ID: 21067256
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The impact of treatment-resistant depression on health care utilization and costs.
    Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM.
    J Clin Psychiatry; 2002 Nov; 63(11):963-71. PubMed ID: 12444808
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A, Greene M, Hartry A, Burudpakdee C.
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.